Non-invasive Measurement of Hepatic Fibrosis in Patients Using Methotrexate.

Non-invasive Measurement of Hepatic Fibrosis in Patients Using Methotrexate. - Measurement of Hepatic Fibrosis in Patients Using Methotrexate.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30803

Enrollment

1600

Registered

2007-07-05

Start date

2008-05-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver damage en Liver disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patiënts with Rheumatoid Arthritis - Use of Methotrexate - Disturbance of liver enzymes > 1,7 times upper limit - > 18 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Non-invasive Assessment of Fibrosis or Cirrhosis during treatment with Methotrexate in patients with Rheumatoid Arthritis and/or Psoriasis with the Fibroscan.	—

Secondary

Measure	Time frame
Incidence of liver enzyme disturbances in patients treated with Methotrexate for Rheumatoid Arthritis and Psoriasis. Incidence of Fibrosis or Cirrhosis in patients treated with Methotrexate for Rheumatoid Arthritis and Psoriasis.	—

Countries

Netherlands

Outcome results